Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026)

Alto Neuroscience has reported Operating Expenses over the past 4 years, most recently at $27.1 million for Q1 2026.

  • Quarterly results put Operating Expenses at $27.1 million for Q1 2026, up 73.12% from a year ago — trailing twelve months through Mar 2026 was $77.8 million (up 11.34% YoY), and the annual figure for FY2025 was $66.4 million, down 3.27%.
  • Operating Expenses reached $27.1 million in Q1 2026 per ANRO's latest filing, up from $17.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.1 million in Q1 2026 and bottomed at $7.2 million in Q1 2023.
  • Median Operating Expenses over the past 4 years was $15.7 million (2025), compared with a mean of $15.4 million.
  • The largest annual shift saw Operating Expenses soared 101.0% in 2024 before it decreased 20.84% in 2025.
  • Over 4 years, Operating Expenses stood at $11.8 million in 2023, then skyrocketed by 44.47% to $17.0 million in 2024, then grew by 0.34% to $17.1 million in 2025, then skyrocketed by 59.12% to $27.1 million in 2026.
  • Business Quant data shows Operating Expenses for ANRO at $27.1 million in Q1 2026, $17.1 million in Q4 2025, and $15.0 million in Q3 2025.